Fredrik L Andersson

Summary

Affiliation: AstraZeneca R and D

Publications

  1. pmc Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD
    Elisabeth Stahl
    Dept of Respiratory Medicine, University Hospital, Lund, Sweden
    Health Qual Life Outcomes 1:18. 2003
  2. pmc Health-related quality of life is related to COPD disease severity
    Elisabeth Stahl
    Department of Respiratory Medicine and Allergology, University Hospital, SE 221 85 Lund, Sweden
    Health Qual Life Outcomes 3:56. 2005
  3. ncbi request reprint Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice
    F Andersson
    Health Economics and Outcomes Research, AstraZeneca R and D Lund, Sweden
    Ann Allergy Asthma Immunol 86:537-44. 2001
  4. ncbi request reprint Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study
    F Andersson
    AstraZeneca R and D Lund, Sweden
    Respir Med 95:505-12. 2001
  5. ncbi request reprint The costs of exacerbations in chronic obstructive pulmonary disease (COPD)
    F Andersson
    Health Economics and Outcomes Research, AstraZeneca R and D, Lund, Sweden
    Respir Med 96:700-8. 2002
  6. ncbi request reprint The impact of exacerbations on the asthmatic patient's preference scores
    Fredrik Andersson
    Health Economics and Outcomes Research, AstraZeneca R and D, Lund, Sweden
    J Asthma 40:615-23. 2003
  7. ncbi request reprint Hospital use for COPD patients during the last few years of their life
    Fredrik L Andersson
    Health Economics and Outcomes Research, AstraZeneca R and D, and Department of Respiratory Medicine and Allergology, Lund University Hospital, 221 87, Sweden
    Respir Med 100:1436-41. 2006
  8. ncbi request reprint Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?
    Paul S J Miller
    AstraZeneca, HEOR Clinical Science, Parklands FE2 D 4, Alderley Park, SK10 4TG UK
    Stroke 36:360-6. 2005
  9. ncbi request reprint The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study
    Bernd Brüggenjürgen
    Institute for Social Medicine, Epidemiology and Health Economics, Charite Universitatsmedizin Berlin, Germany
    Value Health 10:137-43. 2007
  10. ncbi request reprint Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study
    Kevin Weiss
    Institute for Health Studies, Midwest Center for Health Services and Policy Research, Hines, VA, USA
    Pediatr Allergy Immunol 17:21-7. 2006

Detail Information

Publications11

  1. pmc Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD
    Elisabeth Stahl
    Dept of Respiratory Medicine, University Hospital, Lund, Sweden
    Health Qual Life Outcomes 1:18. 2003
    ..Age correlated significantly with the degree of the subject's opinion of the ease of completion of five outcomes instruments, while the influence of gender, socio-economic status and disease severity was not statistically significant...
  2. pmc Health-related quality of life is related to COPD disease severity
    Elisabeth Stahl
    Department of Respiratory Medicine and Allergology, University Hospital, SE 221 85 Lund, Sweden
    Health Qual Life Outcomes 3:56. 2005
    ..The aim of this study was to evaluate the association between health-related quality of life (HRQL) and disease severity using lung function measures...
  3. ncbi request reprint Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice
    F Andersson
    Health Economics and Outcomes Research, AstraZeneca R and D Lund, Sweden
    Ann Allergy Asthma Immunol 86:537-44. 2001
    ..Budesonide and sodium cromoglycate are both recommended as maintenance therapy for childhood asthma...
  4. ncbi request reprint Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study
    F Andersson
    AstraZeneca R and D Lund, Sweden
    Respir Med 95:505-12. 2001
    ..Adding formoterol to budesonide can thus be considered to be cost-effective...
  5. ncbi request reprint The costs of exacerbations in chronic obstructive pulmonary disease (COPD)
    F Andersson
    Health Economics and Outcomes Research, AstraZeneca R and D, Lund, Sweden
    Respir Med 96:700-8. 2002
    ..In conclusion, costs varied considerably with the severity of the exacerbation as well as with the severity of COPD. The prevention of moderate-to-severe exacerbations could be very cost-effective and improve the quality of life...
  6. ncbi request reprint The impact of exacerbations on the asthmatic patient's preference scores
    Fredrik Andersson
    Health Economics and Outcomes Research, AstraZeneca R and D, Lund, Sweden
    J Asthma 40:615-23. 2003
    ..In conclusion, asthmatic patients are severely affected in their health and daily living by mild and severe exacerbations. Considerable effort should be made to reduce the number and severity of exacerbations...
  7. ncbi request reprint Hospital use for COPD patients during the last few years of their life
    Fredrik L Andersson
    Health Economics and Outcomes Research, AstraZeneca R and D, and Department of Respiratory Medicine and Allergology, Lund University Hospital, 221 87, Sweden
    Respir Med 100:1436-41. 2006
    ..Finally, COPD patients often have a number of concomittant diseases which may affect diagnosis and healthcare resource use. The economic and policy implications of these main findings need to be further examined...
  8. ncbi request reprint Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?
    Paul S J Miller
    AstraZeneca, HEOR Clinical Science, Parklands FE2 D 4, Alderley Park, SK10 4TG UK
    Stroke 36:360-6. 2005
    ..The objective of this study was to evaluate whether the cost benefits of anticoagulation for stroke prevention in AF may currently be underestimated by existing economic models that do not distinguish between different stroke outcomes...
  9. ncbi request reprint The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study
    Bernd Brüggenjürgen
    Institute for Social Medicine, Epidemiology and Health Economics, Charite Universitatsmedizin Berlin, Germany
    Value Health 10:137-43. 2007
    ....
  10. ncbi request reprint Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study
    Kevin Weiss
    Institute for Health Studies, Midwest Center for Health Services and Policy Research, Hines, VA, USA
    Pediatr Allergy Immunol 17:21-7. 2006
    ....
  11. ncbi request reprint Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    John J V McMurray
    Department of Cardiology, Level 4, Western Infirmary, Glasgow, Scotland, UK
    Eur Heart J 27:1447-58. 2006
    ..We have carried out a prospective economic analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme...